Favipiravir in the Battle with Respiratory Viruses.

Journal: Mini Reviews In Medicinal Chemistry
Treatment Used: Favipiravir
Number of Patients: 0
Published:
MediFind Summary

Summary: This article discusses the use of favipiravir in the treatment of patients with COVID-19 and other respiratory viruses.

Conclusion: Favipiravir may be effective in the treatment of patients with COVID-19 and other respiratory viruses.

Abstract

Among antiviral drugs, the vast majority targets only one or two related viruses. The conventional model, one virus - one drug, significantly limits therapeutic options. Therefore, in the strategy of controlling viral infections, there is a necessity to develop compounds with pleiotropic effects. Favipiravir (FPV) emerged as a strong candidate to become such a drug. The aim of the study is to present up-to-date information on the role of favipiravir in the treatment of viral respiratory infections. The anti-influenza activity of favipiravir has been confirmed in cell culture experiments, animal models, and clinical trials. Thoroughly different - from the previously registered drugs - mechanism of action suggests that FVP can be used as a countermeasure for the novel or re-emerging influenza virus infections. In recent months, favipiravir has been broadly investigated due to its potential efficacy in the treatment of COVID-19. Based on preclinical and clinical studies and a recently published meta-analysis it seems that favipiravir may be a promising antiviral drug in the treatment of patients with COVID-19. FPV is also effective against other RNA respiratory viruses and may be a candidate for the treatment of serious infections caused by human rhinovirus, respiratory syncytial virus, metapneumovirus, parainfluenza viruses and hantavirus pulmonary syndrome.

Authors
Julia Smyk, Anna Majewska

Similar Latest Advances